- Written by Professor Simon Chapman,
Nicotine replacement therapy has been portrayed as the best way to wean smokers off their habit. But as Simon Chapman, Professor of Public Health, University of Sydney, explains, NRT is not the cure-all it has been cracked up to be.
Nicotine replacement therapy (NRT) became available in Australia in 1984 (gum) and 1993 (patches), first as prescription-only items. From 1988, they started becoming available as an over-the-counter item, with patches available without prescription from 1997. Today, some forms of NRT can even be bought in supermarkets.
If prescribed, NRT attracts a government subsidy. In the 17 months from July 2013 to Dec 2014, data provided by the Department of Health show 199,818 NRT scripts cost the government A$8,617,804.
But 31 years later, what should governments do if data show that NRT is little better, or even a good deal worse, at helping smokers quit than if they try to do it cold turkey?
- Written by University of Newcastle - Clinical Investigators
Australian health researchers are investigating the use of the Australian Government's My Health Record (MyHR). They are using an online survey to better understand Australian medical practitioners (GPs and Specialists), practice nurses and practice managers' use and views of the MyHR.
Chief clinical investigator, Associate Professor Bronwyn Hemsley from the University of Newcastle, has a long standing interest in the use of internet technologies to improve patient care and hopes the research will elucidate the barriers to more effective use of the MyHR.
The survey takes under 10 minutes to complete and has 5 demographic questions, followed by 12 MyHR questions. Participation is private and confidential.
The research is funded by the National Health and Medical Research Council of Australia and has Ethics Approval Number H-2014-0041.
The survey closes on 22 January 2018.
- Written by Andrew Binns
“James Packer takes a deep draw of his menthol cigarette and for a few moments stares out the window at the lush polo field…”
- Damon Kitney, “I was terrified”, Weekend Australian Magazine, Oct 21-22 2017.
Among the many misconceptions that smokers have about their habit is that weaker/milder cigarettes are “better”, although there is no evidence for this. Indeed, they can be worse because of increased inhaling to build up nicotine levels. As for mentholated cigarettes - first developed by Lloyd "Spud" Hughes of Mingo Junction, Ohio in 1924 - evidence shows that the cool (or ‘Kool’) ingestion of menthol causes an increased metabolism of nicotine.
Regardless of the scientific evidence about the damage that smoking causes to human health - the practice has a 68% death rate, a statistic that few smokers are aware of - there are many myths about consumption, and even more challenges about quitting.
- Written by David Guest
The Royal Australian College of General Practitioners is seeking feedback on GP’s engagement with Primary Health Networks (PHNs).
A recent survey conducted by the College found that only 10% of members reported a significant presence or involvement with their PHN.
PHNs are the government's primary tool for developing and improving primary care in Australia. As general practitioners play a pivotal role in primary health care coordination, the College is seeking to better understand the GP’s place in the current PHN structure.
- Written by Robin Osborne
It may be a long way from Vancouver, Canada to Casino, northern NSW but if all goes according to plan the “beef capital of Australia” may be set to rename itself the nation’s cannabis capital.
In a statement on 27 September 2017 the listed Canadian company PUF Ventures Inc announced it would enter into a strategic partnership with Richmond Valley Council to construct a 1 million-square-foot (9.3ha) greenhouse operation that could become the southern hemisphere’s largest cannabis operation.
Along with growing some 100,000 kilograms of high quality cannabis a year - not to be confused with the low-THC hemp for fibre - the operation will include large-scale manufacturing, processing and office facilities for producing “medicinal cannabis and associated products”.
The term ‘associated products’ hints of the company’s ambitions beyond the newly emerging world of medicinal cannabis prescribing.
Page 14 of 86